Lördag 11 Oktober | 08:14:44 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2025-10-30 08:00 Kvartalsrapport 2025-Q3
2025-08-21 - Kvartalsrapport 2025-Q2
2025-05-30 - X-dag ordinarie utdelning ONCOZ 0.00 SEK
2025-05-28 - Årsstämma
2025-05-15 - Kvartalsrapport 2025-Q1
2025-03-03 - Extra Bolagsstämma 2025
2025-02-20 - Bokslutskommuniké 2024
2024-11-18 - Kvartalsrapport 2024-Q3
2024-08-09 - Kvartalsrapport 2024-Q2
2024-06-03 - X-dag ordinarie utdelning ONCOZ 0.00 SEK
2024-05-31 - Årsstämma
2024-05-21 - Kvartalsrapport 2024-Q1
2024-02-15 - Bokslutskommuniké 2023
2023-11-01 - Extra Bolagsstämma 2023
2023-10-31 - Kvartalsrapport 2023-Q3
2023-08-31 - Kvartalsrapport 2023-Q2
2023-06-01 - X-dag ordinarie utdelning ONCOZ 0.00 SEK
2023-05-31 - Årsstämma
2023-05-16 - Kvartalsrapport 2023-Q1
2023-02-14 - Bokslutskommuniké 2022
2022-11-15 - Kvartalsrapport 2022-Q3
2022-08-16 - Kvartalsrapport 2022-Q2
2022-05-24 - X-dag ordinarie utdelning ONCOZ 0.00 SEK
2022-05-23 - Årsstämma
2022-05-17 - Kvartalsrapport 2022-Q1
2022-02-15 - Bokslutskommuniké 2021
2021-12-07 - Extra Bolagsstämma 2021
2021-11-16 - Kvartalsrapport 2021-Q3
2021-08-17 - Kvartalsrapport 2021-Q2
2021-05-18 - Kvartalsrapport 2021-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
OncoZenge är ett svenskt läkemedelsbolag som utvecklar behandlingar för smärtlindring hos patienter som lider av oral smärta orsakad av strålbehandling och kemoterapi mot cancer. Bolagets produktkandidat är efter genomförda fas 2-studier under vidare utveckling till grund för ansökan om regulatoriska marknadsgodkännanden och kommersialisering. OncoZenge har sitt huvudkontor i Bromma.
2025-10-08 19:50:00

STOCKHOLM, October 8, 2025. In accordance with the resolution of the Annual General Meeting on May 28, 2025, the Chairman of the Board has contacted the company's three largest shareholders or owner groups in terms of votes, each of whom was offered to appoint a representative to constitute the company's Nomination Committee for the Annual General Meeting for the financial year January - December 2025. All three largest shareholders or owner groups have accepted to form the Nomination Committee together with the Chairman of the Company's Board of Directors.

OncoZenge's Nomination Committee for the Annual General Meeting for the financial year January - December 2025 consists of:

  • Niclas Holmgren
  • Karl Tobieson, appointed by Linc AB
  • Andreas Özbek
  • Daniel Ehrenstråhle, Chairman of the Board

The Nomination Committee together represents 28.5 percent of the voting rights of all voting shares in the company as of September 30, 2025.

The Nomination Committee's task is to present proposals to the Annual General Meeting for the financial year January - December 2025 regarding the election of the Chairman of the Board and other members of the Board, Board fees and other remuneration to the Board members, as well as election and remuneration of auditors.

The Annual General Meeting for the financial year January - December 2025 will be held on May 27, 2026. Shareholders who wish to submit proposals to OncoZenge's Nomination Committee can do so by e-mail to info@oncozenge.se no later than April 10, 2026.